EB 1053

potent inhibitor of bone resorption

Also Known As:

EB-1053; Phosphonic acid, (1-hydroxy-3-(1-pyrrolidinyl)propylidene)bis-, disodium salt; disodium 1-hydroxy-3-(1-pyrrolidinyl)propylidene-1,1-bisphosphonate

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Organic Chemicals: 133
- Organophosphorus Compounds: 300
  - Organophosphonates: 424
    - Diphosphonates: 11565
      - EB 1053: 2
Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyrrolidines: 115
    - EB 1053: 2

Experts

1.	Colston, K W: 2 articles (08/2003 - 04/2000)
2.	Pirianov, G: 2 articles (08/2003 - 04/2000)
3.	Binderup, L: 1 article (08/2003)
4.	Bramm, E: 1 article (08/2003)
5.	Hamberg, K J: 1 article (08/2003)
6.	Arnett, T R: 1 article (04/2000)
7.	Mansi, J L: 1 article (04/2000)
8.	Senaratne, S G: 1 article (04/2000)

Related Diseases

1.	Neoplasms (Cancer) 08/01/2003 - "for 4 weeks) alone and in combination with pamidronate (APD 0.4 mg/kg per day s.c.) or the same dose of the bisphosphonate EB 1053 caused substantial tumor regression. "
2.	Breast Neoplasms (Breast Cancer) 04/01/2000 - "We have investigated the in vitro effects of bisphosphonates zoledronate, pamidronate, clodronate and EB 1053 on growth, viability and induction of apoptosis in three human breast cancer cell lines (MDA-MB-231, Hs 578T and MCF-7). "

Related Drugs and Biologics

1.	Diphosphonates (Bisphosphonates)
2.	Pamidronate (Aredia)
3.	Clodronic Acid (Clodronate)
4.	Zoledronic Acid (Zometa)